Unconventional T Cells Offer New Hope Against Urological Cancers

Urological cancers may be hiding an underused layer of immune surveillance, according to a new review that places unconventional T cells at the centre of emerging research in prostate cancer, bladder cancer and renal cell carcinoma. These immune cells differ from the conventional αβ T lymphocytes that dominate many cancer immunology studies. Rather than relying primarily on peptide fragments displayed by classical major histocompatibility complex molecules, they can detect metabolic imbalance, microbial signals and cellular stress through alternative recognition systems. Their rapid, tissue-oriented responses could make them valuable targets for diagnosis and treatment, particularly in tumours where conventional immune responses are weak or suppressed.

The term “unconventional T cells” covers several distinct populations, including γδ T cells, mucosal-associated invariant T cells, natural killer T cells, double-positive T cells that carry both CD4 and CD8, and double-negative T cells that carry neither marker. Although these groups differ in their receptors, tissue distribution and activation requirements, they share a capacity for responding quickly to danger signals. This places them between classical adaptive immunity and innate immune defence. In a tumour, that position may allow them to sense changes before a conventional antigen-specific response has fully developed.

γδ T cells are among the most extensively studied members of this group. Their receptors can recognize stress-associated molecules and small phosphorylated metabolites, often with assistance from butyrophilin family proteins. Some γδ T cells can kill malignant cells directly by releasing perforin and granzymes or by activating death receptors on tumour cells. Others produce inflammatory mediators such as interferon-γ and tumour necrosis factor, which can strengthen local immune activity. However, their behaviour is not uniformly antitumour. Depending on the tissue environment, γδ T cells may also release interleukin-17 or acquire regulatory functions that support inflammation, tissue remodelling or tumour progression.

Mucosal-associated invariant T cells, known as MAIT cells, provide another potential route into the tumour microenvironment. These cells carry a relatively restricted T-cell receptor and are best known for recognizing microbial-derived vitamin B metabolites presented by the non-classical molecule MR1. Because urinary organs are connected to microbial environments and can be affected by infection, inflammation and tissue injury, MAIT cells may encounter signals that influence tumour development and treatment response. In cancer, they can display cytotoxic activity, but chronic stimulation, nutrient limitation and inhibitory checkpoint signals may drive them towards dysfunction or exhaustion.

Natural killer T cells recognize lipid and glycolipid antigens presented by CD1d rather than peptide antigens displayed by classical MHC molecules. Their rapid production of cytokines gives them the ability to shape the behaviour of other immune cells, including natural killer cells, macrophages and conventional T lymphocytes. In urological cancers, this capacity could be important because the tumour microenvironment is not simply a collection of malignant cells. It is a constantly changing ecosystem containing suppressive myeloid cells, altered blood vessels, cancer-associated fibroblasts and abnormal concentrations of oxygen, glucose and lipids. NKT cells may respond to these changes, but the same environment can also prevent them from maintaining effective antitumour activity.

The review also highlights double-positive and double-negative T lymphocytes, populations that are less well understood in cancer than conventional CD4-positive or CD8-positive cells. Double-positive T cells have been detected in peripheral tissues and tumours, where they may possess strong cytotoxic functions or represent cells undergoing functional reprogramming. Double-negative T cells are similarly diverse. Some can attack tumour cells, while others may regulate immune responses or contribute to immune suppression. Their presence alone therefore cannot be interpreted as evidence of effective tumour control. Researchers must determine which receptors they express, what signals activate them and whether they remain functional after entering a tumour.

Across prostate cancer, bladder cancer and renal cell carcinoma, the activity of unconventional T cells appears to depend heavily on context. Tumour type, disease stage, previous treatment, tissue location and the composition of the local microbiome may all influence whether these cells become protective or harmful. A cell population that produces inflammatory cytokines in one setting may become exhausted in another. Likewise, a subset that kills tumour cells in laboratory cultures may behave differently inside a nutrient-deprived, oxygen-poor tumour containing high levels of inhibitory molecules such as PD-L1 and transforming growth factor-β.

These biological differences could have direct therapeutic consequences. Checkpoint inhibitors might restore activity in unconventional T cells, but only if the relevant populations are present and retain the molecular machinery required for reactivation. Adoptive cell therapy could offer another strategy by expanding selected γδ T cells, MAIT cells or other unconventional populations outside the body before reinfusion. Researchers may also be able to engineer these cells, alter their receptors or combine them with agents that change tumour metabolism. In bladder cancer, the established use of Bacillus Calmette–Guérin, or BCG, provides a particularly interesting platform because the therapy already depends on immune stimulation within the urinary tract.

Combination treatments involving checkpoint blockade, adoptive cell transfer and BCG-based immunotherapy are now being explored in clinical research, although major questions remain about patient selection and safety. The review argues that future studies should move beyond simply counting unconventional T cells in tumour samples. Investigators will need to map their receptor repertoires, identify the antigens and metabolites they recognize, measure their functional state and determine how treatment reshapes them over time. Single-cell sequencing, spatial transcriptomics, advanced imaging and analysis of tumour metabolism could help reveal which cells are actively fighting cancer and which have been diverted into regulatory roles.

The emerging picture is of an immune system with more sensors, circuits and failure points than conventional cancer models have captured. Unconventional T cells can detect signals that peptide-focused approaches may miss, making them attractive candidates for new biomarkers and therapies in urological oncology. Yet their flexibility is also their greatest complication: the same population may be cytotoxic, inflammatory or immunoregulatory depending on its surroundings. By clarifying how these cells recognize tumour-associated stress and how cancer alters their behaviour, researchers may turn a poorly understood branch of immunity into a precise tool against prostate, bladder and kidney cancers.